ONO-2020-02: A Phase II, 26-week, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetics, and efficacy of ONO-2020 in patients with mild to moderate Alzheimer#s Disease

Detalles del proyecto

EstadoFinalizado
Fecha de inicio/Fecha fin1/14/251/14/26

Financiación

  • IQVIA RDS Incorporated: 44.300,00 US$